Minimizing recurrent venous thromboembolism
- PMID: 31345836
- DOI: 10.1136/bmj.l4686
Minimizing recurrent venous thromboembolism
Erratum in
-
Correction for vol. 366, p.BMJ. 2019 Jul 30;366:l4921. doi: 10.1136/bmj.l4921. BMJ. 2019. PMID: 31362978
Conflict of interest statement
Competing interests: BB and HMK report that they have been experts (on behalf of the plaintiff) for litigation related to a specific type of IVC filters. HMK was a recipient of a research grant, through Yale, from Medtronic and the US Food and Drug Administration to develop methods for post-marketing surveillance of medical devices; is a recipient of a research agreement with Medtronic and Johnson & Johnson (Janssen), through Yale, to develop methods of clinical trial data sharing; works under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures that are publicly reported; chairs a Cardiac Scientific Advisory Board for UnitedHealth; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science and the Physician Advisory Board for Aetna; and is the founder of Hugo, a personal health information platform.
Comment on
-
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363. BMJ. 2019. PMID: 31340984 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical